• 020 7251 3322
  • 226 Walmer Road, London W11 4ET
Menu

NICE’s decision for Aimovig for the prevention of migraine

26 September 2019

 

NATIONAL MIGRAINE CENTRE’S RESPONSE TO THE NICE DECISION FOR AIMOVIG® (ERENUMAB) FOR THE PREVENTION OF MIGRAINE

 

 

Dr David Bloomfield, CEO at the National Migraine Centre, said “We are saddened to learn that the new migraine treatment Aimovig (Erenumab) from Novartis has not been approved by NICE for use within the NHS in England and Wales. Current treatment options are not universally useful and this decision removes both hope and options for those people unable to find relief using current treatments. We hope that in the fullness of time as more data becomes available this decision might be revisited.”

Dr Katy Munro, Headache Specialist at the National Migraine Centre, said “We have been very disappointed once again to hear this news. This new class of drugs is showing good promise for those patients with Chronic Migraine and especially those who have tried and failed many previous preventers including Botox.

We have recently surveyed patients who have had this treatment via our service and have been encouraged by their positive responses to treatment and the low incidence of side effects.

We have treated nearly 200 patients with Aimovig since September last year. 69% said it had improved their quality of life and 75% said they would recommend it to others. Of course, these are patients who can afford to pay for it. We see many desperate migraine sufferers who simply cannot finance this kind of treatment themselves. It seems strange that Aimovig is approved in Scotland but not in England and Wales. We understand the pressures on NHS budgets but would hope that in future these innovative new treatments will be more widely available.

Key findings from National Migraine Centre’s Aimovig 3 month patient feedback survey:
• 77% of patients continued Aimovig treatment.
• Pain scores halved in severity for Aimovig patients.
• Headache days dropped from an average of 19 days per month to 10.
• 69% of patients being treated with Aimovig found that their quality of life improved.
• 75% of patients being treated with Aimovig said they would recommend the drug to others.

For help and further information, call the National Migraine Centre on 020 7251 3322 or visit www.nationalmigrainecentre.org.uk.

—ENDS—

MEDIA ENQUIRIES: contact Charlotte Burr or Swati Raina on Tel: 020 7251 7806. Email: charlotte.burr@nationalmigrainecentre.org.uk. Headache Specialist Doctors and David Bloomfield, CEO of the National Migraine Centre, are available for interviews. Patient case studies are also available for interviews.

Notes to editors:
National Migraine Centre is the only national charity that provides treatment for migraine and headache sufferers. It was founded in 1980 by two neurologists and has treated more than 60,000 patients. In addition to this the National Migraine Centre is committed to advocating their cause and educating healthcare professionals. Migraine sufferers can self-refer to see a headache specialist doctor at the centre. Visit our website: www.nationalmigrainecentre.org.uk

Back